If you have been reading about reversed-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-10. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Immediately after the 1948 war, the Israel-Palestinian conflict shifted to a low intensity conflict between the IDF and Palestinian fedayeen. In the 1956 Suez Crisis, the IDF's first serious test of strength after 1949, the new army captured the Sinai Peninsula from Egypt, which was later returned. In the 1967 Six-Day War, Israel conquered the Sinai Peninsula, Gaza Strip, West Bank (including East Jerusalem) and Golan Heights from the surrounding Arab states, changing the balance of power in the region as well as the role of the IDF. In the following years leading up to the Yom Kippur War, the IDF fought in the War of Attrition against Egypt in the Sinai and a border war against the Palestine Liberation Organization (PLO) in Jordan, culminating in the Battle of Karameh. The surprise of the Yom Kippur War and its aftermath completely changed the IDF's procedures and approach to warfare. Organizational changes were made and more time was dedicated to training for conventional warfare. In the following years the army's role slowly shifted again to low-intensity conflict, urban warfare and counter-terrorism. An example of the latter was the successful 1976 Operation Entebbe commando raid to free hijacked airline passengers being held captive in Uganda. During this era, the IDF also mounted a successful bombing mission in Iraq to destroy its nuclear reactor. It was involved in the Lebanese Civil War, initiating Operation Litani and later the 1982 Lebanon War, where the IDF ousted Palestinian guerilla organizations from Lebanon.
This exclusion is to ensure that a blended Scotch whisky produced from single malt(s) and single grain(s) distilled at the same distillery does not also qualify as single malt Scotch whisky or single grain Scotch whisky. Nearly 90% of the bottles of Scotch sold per year are blended whiskies. Three types of blends are defined for Scotch whisky:
OHPH, also known as hydroxyprogesterone enanthate (OHPE), as well as 17α-hydroxyprogesterone heptanoate or 17α-hydroxypregn-4-ene-3,20-dione 17α-heptanoate, is a synthetic pregnane steroid and a derivative of progesterone and 17α-hydroxyprogesterone. It is a progestogen ester; specifically, it is the C17α heptanoate (enanthate) ester of 17α-hydroxyprogesterone. Analogues of OHPH include the more well-known medications hydroxyprogesterone acetate and hydroxyprogesterone caproate (hydroxyprogesterone hexanoate). The C3 benzilic acid hydrazone of OHPH, hydroxyprogesterone heptanoate benzilic acid hydrazone (OHPHBH), is known and has been studied in animals. In terms of chemical structure, OHPH is very similar to hydroxyprogesterone caproate, differing from it only in having one additional carbon in its fatty acid ester chain.
Sources: en.wikipedia.org
FDAA consists of a D-amino acid and a fluorophore (coupled through the amino acid side chain). The D-amino acid backbone is required for its incorporation into the bacterial peptidoglycan through the activity of DD-transpeptidases. Once being incorporated, one can use fluorescence-detection techniques to visualize the location of new PG formation as well as the growth rate. D-Alanine is the most well-studied D-amino acid for FDAA development because it is a naturally existing residue in bacterial peptidoglycan structures. On the other hand, various fluorophores have been employed for FDAA applications and each has its features. For example, coumarin-based FDAA (HADA) is small enough to penetrate the bacterial outer membranes and thus is widely used for gram-negative bacterial studies; while TAMRA-based FDAA (TADA) features its high brightness and photo/thermo-stability, which is suitable for super-resolution microscopy (strong excitation light is used).
=== Modern usage === As part of standard TB chemotherapy, isoniazid is now typically administered alongside at least three other drugs—ethambutol, pyrazinamide, and rifampin—for six to nine months. Isoniazid is also included on the World Health Organization's List of Essential Medicines. The World Health Organization classifies isoniazid as critically important for human medicine.
==== Beverages ==== Carbon dioxide is used to produce carbonated soft drinks and soda water. Traditionally, the carbonation of beer and sparkling wine came about through natural fermentation, but many manufacturers carbonate these drinks with carbon dioxide recovered from the fermentation process. In the case of bottled and kegged beer, the most common method used is carbonation with recycled carbon dioxide. With the exception of British real ale, draught beer is usually transferred from kegs in a cold room or cellar to dispensing taps on the bar using pressurized carbon dioxide, sometimes mixed with nitrogen. The taste of soda water (and related taste sensations in other carbonated beverages) is an effect of the dissolved carbon dioxide rather than the bursting bubbles of the gas. Carbonic anhydrase 4 converts carbon dioxide to carbonic acid leading to a sour taste, and also the dissolved carbon dioxide induces a somatosensory response.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.